Abstract:OBJECTIVE To explore the effects of pioglitazone on insulitis and diabetes and relevant mechanism. METHODS Seventy-three female non-obese diabetic (NOD)/Lt mice aged 4 weeks were randomly divided into 3 groups, control group (n = 25, fed with regular diet), low dosage pioglitazone group (n = 23, pioglitazone of the concentration of 0.01% was added into the feed) and high dosage pioglitazone group (n = 25, pioglitazone of the concentration of 0.04% was added into the feed). The mice were killed when diabetes developed or they reached the age of 30 weeks. The body weight and amount of food intake were measured every week and the amount of drug intake was calculated. Urine glucose was checked weekly from week 10 to week 30. When urine glucose was positive and relevant symptoms appeared, blood glucose was measured. The criterion of diagnosis of diabetes was the consecutive blood glucose level > or = 16.7 mmol/L for 2 times. At the 12th week 4-7 mice from the 3 groups respectively were killed and their pancreases were removed to be scored on insulitis by HE staining, the spleen cells were cultured. The IL-4 and IFN-r levels in serum and supernatants of spleen cell cultures were measured by ELISA. The pancreatic IFN-r mRNA level was tested using RT-PCR method. RESULTS (1) At the age of 30 weeks, the diabetes incidence rates was 80% (20/25) in the control group, 60.9% (14/23) in the low dose group, and 60% (15/25) in the high dose group (P > 0.05). At the following time points the diabetes incidence rates of the 2 treated groups were lower than that of the control group (all P < 0.05): (1) 0% in the low dose group vs 16%: of the control group at the age of 100 days, and 39% vs 68% at the age of 185 days; and (2) 0% in the high dose group vs 16% in the control group at the age of 110 days, 4% vs 24% at the age of 120 days, and 12%vs 36% at the age of 135 days. (2) There was no difference in insulitis scores between the control group and low dose or high dose groups at the age of 12 weeks (1.99 +/- 0.75 vs 1.01 +/- 0.68 and 1.19 +/- 0.84, both P > 0.05), however, the score of the combined pioglitazone group (low dose group + high dos group) was significantly higher than that of the control group (1.12 +/- 0.75 vs 1.99 +/- 0.75, P < 0.05). (3) There was no differences in the IL-4/IFN-r ratios in serum and splenocyte culture supernatant and pancreatic IFN-r mRNA levels among the three groups (all P > 0.05). CONCLUSION Pioglitazone, to some extent, lessens the insulitis severity and delays the diabetes onset. Its mechanism may be unrelated to immune deviation of Th1 to a Th2.

Therapeutic effects of pioglitazone combined with insulin on newly diagnosed latent autoimmune diabetes in adult

Rosiglitazone Combined with Insulin Preserves Islet Beta Cell Function in Adult-Onset Latent Autoimmune Diabetes (Lada).

Rosiglitazone Preserves Islet Β-Cell Function of Adult-Onset Latent Autoimmune Diabetes in 3 Years Follow-Up Study

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains Β-Cell Function in Patients with Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study.

Altered T‐cell Subsets and Transcription Factors in Latent Autoimmune Diabetes in Adults Taking Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor: A 1‐year Open‐label Randomized Controlled Trial

Islet Function And Insulin Sensitivity In Latent Autoimmune Diabetes In Adults Taking Sitagliptin: A Randomized Trial

Clinical efficacy of glimepiride combined with pioglitazone on glycemic control in type 2 diabetes patients

Effects of Rosiglitazone on Islet Β Cell Function in LADA Patients with Low Titer of Glutamic Acid Decarboxylase Antibody

Effects of Pioglitazone on Serum Adiponectin Levels and Insulin Resistance in Patients with Type 2 Diabetes Mellitus

[Preventive Effects of Pioglitazone on Diabetes and Relevant Mechanisms, Experimental Study on Non-Obese Diabetic Mice].

[Effects of Rare Islet Autoantibodies on Islet Function in Patients with Latent Autoimmune Diabetes in Adults].

Adding Vitamin D3 to the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin Has the Potential to Protect β-Cell Function in LADA Patients: A One-Year Pilot Study.

Effects of Pioglitazone on Serum Adiponectin and Visfatin Levels in Patients with Type 2 Diabetes Mellitus

Effects of sitagliptin on serum cytokines of latent autoimmune diabetes in adults patients

Pioglitazone in Treatment of Type 2 Diabetes:A Phase Ⅱ Clinical Trial

The effect of insulin versus pioglitazone treatment on the platelet function in type 2 diabetics

[A Randomized, Double Blind, Placebo-Controlled, Parallel and Multicenter Study to Evaluate the Safety and Efficacy of Pioglitazone with Sulphonylurea in Type 2 Diabetic Patients].

Effects of rosiglitazone combined with insulin therapy on islet β cell function and on the level of serum GLP-1 in type 2 diabetic patients

Effect of Pioglitazone on Impaired Glucose Regulation

Multicenter Clinical Trial of Pioglitazone in the Treatment of 2 Type Diabetes

Efficacy and Safety of Pioglitazone Hydrochloride in Treating Type 2 Diabeter